Target Discovery & Validation
Successful medicine begins with target validation and target discovery. Finding the drugable targets remains pivotal to the future R&D success to pharmaceutical companies. HD Biosciences innovative Advanced Gene Manipulation (AGM™) technology and platform solutions serve the clients in the identification and validation of both known and novel targets to understand their contexts of diseases, accelerate the decisions toward Go
or No-Go decision to reduce the risks that impact clients' drug R&D portfolios.
As one of well recognized strong holdings within the company's capabilities, HDB's target validation program has teamed with several major pharmaceutical companies for years to support their programs from oncology, metabolic diseases, translational medicine, to pharmacogenomics. The quality validation results for more than
50 various potential drug targets have delivered to the clients.
Target Manipulation
Target Engagement and MOA
Gene manipulation of in vitro and in vivo
Gene target in contexts of disease model
  Target knockdown, co-knockdown of isoforms, & target overexpression
  Pathway dissecting & phenotypic study
  Conventional knockout, knock-in; conditional regional, organ, or cell type specific knockout in mice
  In vitro functional readout & evaluation
    or isogenic cell lines
  MOA & signaling cascade
  Region specific or cell type specific inducible/reversible transgenic mice
  Targeting specific tissues for MOA study
  BAC/YAC transgenic mice for humanized animal models
  In vivo phenotypic characterizations in various disease models
  Evaluation of target functional roles
  shRNA or sgRNA library screening for target id
  Characterization of target activities & correlations in cell lines with positive and negative effects
  IHC, FACS, WB, qPCR for target engagement
  Rescue study for target specificity confirmation
Translational Predictive Biomarkers
Genetic approaches
  Multiple marker classes including DNA, RNA, protein &
  Viral-based or nonviral-based vectors in specific cell, tissue, organ or systemic gene delivery
    microRNA markers
    & manipulation in vitro & in vivo
  Genetically defined platform including both in vitro & in vivo
  Transgenic technology for model generation; genotyping; breeding & characterization
    disease models
  Targeted genome editing platform (CRISPR/cas 9) for knockout, knock-in of genome manipulation
  Assay development using both mouse & human samples
    at cell types of interest
  Bioinformatics supports
SERVICES
|
THERAPEUTIC AREAS
|
NEWS & EVENTS